DEXAMETHASONE
Genetic Condition
Intergroupe Francophone du MyelomeSmall moleculePhase 3Dormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Genetic Condition cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Aoc 1044 Avidity Biosciences, Inc. | Phase 3 | B |
DEXAMETHASONE Quince Therapeutics S.p.A. | Phase 3 | B |
Nexiguran Ziclumeran Intellia Therapeutics | Phase 3 | B |
Zeleciment Rostudirsen Dyne Therapeutics | Phase 3 | B |
Thalidomide National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | Phase 2 | CCC |
View all 16 →
Same molecule, other indications
DEXAMETHASONE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →